Skip to content
DataLookout
Menu

NCT07940439

A Clinical Trial on the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-9308 Tablet as Monotherapy or Combination Therapy in Participants With Advanced Solid Tumors

StatusNot Yet Recruiting
PhasePhase 1/2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Adverse Events (AEs)
Timeframe: From Day 1 to 40 days after the last dose.
Dose-limiting toxicity (DLT)
Timeframe: From Day 1 to 12 months.
Maximum tolerated dose (MTD)
Timeframe: From Day 1 to 12 months.
Recommended dose for Phase II clinical studies (RP2D)
Timeframe: From Day 1 to 12 months.

Secondary (4)

Progression free survival (PFS)
Objective response rate (ORR)
Disease control rate (DCR)
Duration of response (DOR)

Arms and interventions

HRS-9308 Dose 1 GroupExperimental

HRS-9308, with Dose 1.

HRS-9308 Dose 2 GroupExperimental

HRS-9308, with Dose 2.

HRS-9308 Dose 3 GroupExperimental

HRS-9308, with Dose 3.

HRS-9308 Dose 4 GroupExperimental

HRS-9308, with Dose 4.

HRS-9308 Dose 5 GroupExperimental

HRS-9308, with Dose 5.

Drugs: HRS-9308 Tablet

Sites

1 site in 1 country

  • Fudan University Shanghai Cancer CenterShanghai, Shanghai Municipality, China